The population pharmacokinetics of R- and S-warfarin: Effect of genetic and clinical factors

British Journal of Clinical Pharmacology

Volumn 73, Issue 1, 2012, Pages 66-76

  Lane, Steven ^a   Al Zubiedi, Sameh ^a   Hatch, Ellen ^b   Matthews, Ivan ^c   Jorgensen, Andrea L ^a   Deloukas, Panos ^d   Daly, Ann K ^b   Park, B Kevin ^a   Aarons, Leon ^c   Ogungbenro, Kayode ^c   Kamali, Farhad ^b   Hughes, Dyfrig ^e   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e BANGOR UNIVERSITY   (United Kingdom)

Author keywords

NONMEM software; Pharmacogenetics; Population pharmacokinetics; Warfarin

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; WARFARIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG STRUCTURE; ENANTIOMER; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BODY CONSTITUTION; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETICS, POPULATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; USER-COMPUTER INTERFACE; WARFARIN; YOUNG ADULT;

EID: 83155192795     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04051.x     Document Type: Article

References (36)

1. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodymanics and drug interactions. Semin Vasc Med 2003; 3: 221-30.
2. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
3. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-6.
4. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M. Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-9.
5. Hamberg A, Dahl M, Barban M, Scordo M, Wadelius M, Pengo V, Padrini R, Jonsson E. A PK-PD model for predicting impact of age, CYP2C9 and VKORC1 genotype on individualization of Warfarin therapy. Clin Pharmacol Ther 2007; 81: 529-38.
6. Siguret V, Pautas E, Gouin-Thibault I. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to wearfarin. Vitam Horm 2008; 78: 247-64.
7. Oake N, Fergusson DA, Forster AJ, van Walraven C. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 2007; 176: 1589-94.
8. Pirmohamed M, James S, Meakin S, Green C, Scott A, Walley T, Farrar K, Park B, Breckenridge A. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18, 820 patients. BMJ 2004; 329: 15-9.
9. Wienkers LC, Worden CJ, Storch E, Kunge KL, Rettie AE, Trager WF. Formulation of (R) -8-hydroxywarfarin in human liver microsomers. A new metabolic marker for the (S) mephenytoin hydroxlose P4502C19. Drug Metab Dispos 1996; 24: 610-4.
10. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
11. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003; 13: 247-52.
12. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetski A, Roitelman J, Harats D, Halkin H, Ezra D. Interindividual variability in sensitivity to warfarin-Nature or nurture? Clin Pharmacol Ther 2001; 70: 159-64.
13. Linder MW, Looney S, Adams J, Johnson N, Antonito-Green D, Lacefield N, Bukaveckas B, Valdes R. Warfarin dose adjustment based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis 2002; 14: 227-32.
14. Kamali F, Khan TI, King BD, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H. Contribution of age, body size, and CYP2C9 genotype to anticoagulation response to Warfarin. Clin Pharmacol Ther 2004; 75: 204-12.
15. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A, Breskvar K, Dolzan V. nfluence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005; 5: 193-202.
16. Rettie AE, Tai G. The pharmacogenomics of Warfarin: closing in on personalized medicine. Mol Interv 2006; 6: 223-7.
17. AH W. Use of genetic and nongenetic factors in Warfarin dose algorithms. Pharmacogenomics 2007; 8: 851-61.
18. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur J Clin Pharmacol 2009; 65: 365-75.
19. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005; 44: 1227-46.
20. Hamberg A, Wadelius M, Lindh J, Dahl M, Pengo V, Padrini R, Deloukas P, Rane A, Jonsson E. A pharmacometric model describing the relationship between Warfarin dose and INR response with respect to variations in CYP2C9, VKORC1 and age. Clin Pharmacol Ther 2010; 87: 727-34.
21. Jorgensen A, Al-Zubiedi S, Zhang E, Keniry A, Hanson A, Hughes D, Van Eker D, Stevens L, Hawkins K, Toh C, Kamali F, Daly A, Fitzmaurice D, Coffey A, Williamson P, Deloukas P, Pirmohamed M. Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study, accepted. Pharmacogenet Genomics 2009; 19: 800-12.
22. Naidong W, Lee JW. Development and validation of a high-performance liquid chromatographic method for the quantification of Warfarin emantiomers in human plasma. J Pharm Biomed Anal 1993; 11: 785-92.
23. Matthews I, Aarons L. A population pharmacokinetic model for S-Warfarin application of a mixture model to determine genotype/phenotype. Proceedings of the 15th annual meeting of the population approach group in Europe, Bruges, Belgium 14-6 June 2006.
24. Mosteller R. Simplified Calculation of Body Surface Area. N Engl J Med 1987; 317: 1098.
25. Heimark I, Wienkers L, Kunze K, Gibaldi M, Eddy A, Trager W, O'Reilly R, Goulart D. The mechanism of the interaction between Amiodarone and Warfarin in humans. Clin Pharmacol Ther 1992; 51: 398-407.
26. Wynne H, Kamali F, Edwards C, Long A, Kelly P. Effects of aging upon Warfarin dose requirements: a longitudinal study. Age Ageing 1996; 26: 429-31.
27. Garcia D, Regan S, Crowther M, Hughes R, Hylek E. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005; 127: 2049-56.
28. Ouellet D, Bramson C, Carvajal-Gonzalez S, Roman D, Randinitis E, Remmers A, Gardner MJ. Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin. Br J Clin Pharmacol 2006; 61: 741-5.
29. Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS Jr. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol 2001; 41: 715-22.
30. Uno T, Sugimoto K, Sugawara K, Tateishi T. The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers. J Clin Pharm Ther 2008; 33: 67-73.
31. Warfarin I. Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-64.
32. Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, Zhang L, Zhong MK. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 2008; 64: 1069-84.
33. Hu YF, Tu JH, Tan ZR, Liu ZQ, Zhou G, He J, Wang D, Zhou HH. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica 2007; 37: 315-27.
34. Zhang W, Chang Y-Z, Kan Q-C, Zhang L-R, Li Z-S, Lu H, Wang Z-Y, Chu Q-J, Zhang J. CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur J Clin Pharmacol 2010; 66: 61-6.
35. Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol 2008; 64: 877-82.
36. He BX, Shi L, Qiu J, Tao L, Li R, Yang L, Zhao SJ. A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. Basic Clin Pharmacol Toxicol 2011; 108: 208-13.